Benitec Biopharma (NASDAQ:BNTC) PT Raised to $16.00 at JMP Securities

Benitec Biopharma (NASDAQ:BNTC) had its price objective hoisted by JMP Securities from $10.00 to $16.00 in a report published on Monday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

Benitec Biopharma Trading Down 3.9 %

NASDAQ:BNTC opened at $6.72 on Monday. Benitec Biopharma has a one year low of $1.86 and a one year high of $9.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.62 and a current ratio of 3.62. The firm has a 50-day simple moving average of $4.91 and a 200-day simple moving average of $3.83.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported ($2.64) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Benitec Biopharma stock. Adage Capital Partners GP L.L.C. acquired a new position in Benitec Biopharma Inc. (NASDAQ:BNTC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 189,188 shares of the biotechnology company’s stock, valued at approximately $572,000. Adage Capital Partners GP L.L.C. owned about 7.42% of Benitec Biopharma as of its most recent SEC filing. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.